Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
Hnatiuk AP, Bruyneel AAN, Tailor D, Pandrala M, Dheeraj A, Li W, Serrano R, Feyen DAM, Vu MM, Amatya P, Gupta S, Nakauchi Y, Morgado I, Wiebking V, Liao R, Porteus MH, Majeti R, Malhotra SV, Mercola M.
Hnatiuk AP, et al. Among authors: li w.
Cancer Res. 2022 Aug 3;82(15):2777-2791. doi: 10.1158/0008-5472.CAN-21-3652.
Cancer Res. 2022.
PMID: 35763671
Free PMC article.